Biomarker-led advances in renal cell carcinoma diagnosis, progression monitoring and therapeutic decision-making

Renal cell carcinoma (RCC) diagnosis and management remain challenging due to asymptomatic presentation and limitations in accurately characterizing small renal masses. Noninvasive liquid biopsy biomarkers, including circulating proteins, metabolites, cell-free DNA, microRNAs, and inflammatory markers, have emerged as promising tools for RCC detection, prognostic stratification, and treatment monitoring. Here we review recent advances in blood- and urine-based biomarkers, highlighting key findings such as the diagnostic accuracy of kidney injury molecule-1 (KIM-1), CA15-3, metabolomic signatures, and urinary protein panels, alongside the prognostic relevance of circulating tumor DNA and systemic inflammatory indices. Despite encouraging analytical and clinical validity, no biomarker has yet demonstrated clinical utility due to biological, methodological, and regulatory challenges. Continued efforts focusing on standardized protocols, prospective validation, and integration with imaging and clinical data are essential to translate these biomarkers into personalized RCC management strategies.

Authors

Publication Details

Journal
Figshare
Published
2026-11-12
DOI
https://doi.org/10.6084/m9.figshare.34989303
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Biomarker-led advances in renal cell carcinoma diagnosis, progression monitoring and therapeutic decision-making

Giuseppe Tiziano Lucarelli, Francesco M. Lasorsa, Martina Milella, Pasquale Ditonno et al.
Figshare
Renal cell carcinoma treatment
article

Biomarker-led advances in renal cell carcinoma diagnosis, progression monitoring and therapeutic decision-making

Giuseppe Tiziano Lucarelli, Francesco M. Lasorsa, Martina Milella, Pasquale Ditonno, Monica Rutigliano, Savio Domenico Pandolfo, Matteo Ferro, Francesco Claps, Luca Lambertini
article en

Abstract

Renal cell carcinoma (RCC) diagnosis and management remain challenging due to asymptomatic presentation and limitations in accurately characterizing small renal masses. Noninvasive liquid biopsy biomarkers, including circulating proteins, metabolites, cell-free DNA, microRNAs, and inflammatory markers, have emerged as promising tools for RCC detection, prognostic stratification, and treatment monitoring. Here we review recent advances in blood- and urine-based biomarkers, highlighting key findings such as the diagnostic accuracy of kidney injury molecule-1 (KIM-1), CA15-3, metabolomic signatures, and urinary protein panels, alongside the prognostic relevance of circulating tumor DNA and systemic inflammatory indices. Despite encouraging analytical and clinical validity, no biomarker has yet demonstrated clinical utility due to biological, methodological, and regulatory challenges. Continued efforts focusing on standardized protocols, prospective validation, and integration with imaging and clinical data are essential to translate these biomarkers into personalized RCC management strategies.

Figshare
Good health and well-being
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon